Healthcare, Pharma & Life Sciences

Werfen Wins FDA Clearance, CE Mark for Aptiva APS IgA Assay

Image
Werfen Wins FDA Clearance, CE Mark for Aptiva APS IgA Assay

San Diego – September 24, 2026 -- Werfen has secured U.S. FDA 510(k) clearance and a CE Mark under the EU's IVDR for its Aptiva Antiphospholipid Syndrome (APS) IgA Reagent, completing a three-isotype APS testing portfolio on its Aptiva platform.

Aptiva now covers all three APS antibody isotypes for global laboratories

The clearance means Aptiva offers IgA, IgG, and IgM testing for both anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (aβ2GP1) antibodies, giving laboratories a full antibody profile for antiphospholipid syndrome, an autoimmune disease linked to thrombotic events and pregnancy complications that is often difficult to diagnose due to overlapping clinical symptoms.

Theragen Data Shows 13-Hour Wear Threshold Predicts Spinal Fusion Recovery

Image
Theragen Data Shows 13-Hour Wear Threshold Predicts Spinal Fusion Recovery

Jacksonville, Florida – September 24, 2026 -- Theragen presented machine-learning findings at the Society for Minimally Invasive Spine Surgery (SMISS) 2026 Annual Forum showing that daily wear time of its ActaStim®-S bone growth stimulator predicts clinically meaningful pain improvement after spinal fusion surgery, with benefits plateauing around 13 hours of daily use.

Nearly 7,000 patients and 195,000 patient-days of data feed predictive model

The analysis drew on almost 7,000 patients and approximately 195,000 patient-day observations collected through ActaStim-S, a wearable electrical stimulation device paired with a digital health platform. A standardized device-to-electronic medical record pipeline achieved 99.2% data completeness across the dataset, according to Theragen.

Qualtrics Launches Healthcare XM, Names Dr. Thomas Lee to XM Institute

Image
Qualtrics Launches Healthcare XM, Names Dr. Thomas Lee to XM Institute

Provo, Utah – September 24, 2026 -- Qualtrics unveiled Healthcare XM, a new platform built on Press Ganey's proprietary data and what the company calls the world's largest human experiential dataset, aimed at helping health systems and health plans simulate care changes, predict patient behavior, and act on safety risks before they escalate.

Qualtrics builds Healthcare XM on Press Ganey data to close the industry's experience gap

The platform runs on the Qualtrics XM Data & AI Platform and combines decades of Press Ganey benchmarks, regulatory expertise, and predictive analytics. It covers five domains: patient experience across HCAHPS and CAHPS journeys, member experience including Medicare CAHPS and Stars ratings, workforce engagement and retention, safety and quality signals such as NDNQI and PSO data, and consumer and brand positioning.

Cardiol Expands Phase III Pericarditis Trial to 150 Patients

Image
Cardiol Expands Phase III Pericarditis Trial to 150 Patients

Toronto – September 24, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has hit its 110-patient enrollment target for the pivotal Phase III MAVERIC trial ahead of its end-of-September guidance, and will now expand recruitment to as many as 150 patients.

Blinded review shows fewer recurrences than expected in pericarditis trial

A blinded review of patients randomized 1:1 to CardiolRxTM or placebo found a lower-than-anticipated rate of pericarditis recurrence, according to Cardiol. The MAVERIC Steering Committee recommended the enrollment increase to capture enough clinical events for a statistically robust efficacy read.

President and CEO David Elsley said the company is not aware of any change in routine clinical practice that would explain the reduced recurrence rate, calling the finding encouraging.

DEXIS Launches Portfolio-Wide Upgrade Across Dental Imaging Ecosystem

Image
DEXIS Launches Portfolio-Wide Upgrade Across Dental Imaging Ecosystem

Quakertown, Pa. – September 24, 2026 -- DEXIS unveiled a coordinated set of upgrades spanning hardware, software, cloud and service offerings across its dental imaging ecosystem, unveiled during the company's ILLUMINATE virtual keynote.

NOMAD Pro 3 upgrades handheld X-ray hardware with improved image quality and durability

The new NOMAD Pro 3 builds on DEXIS' handheld X-ray system, adding enhanced image quality and durability while maintaining safety-first engineering standards. Separately, the ORTHOPANTOMOGRAPH OP 3D gains a Motion Correction feature that reduces the impact of patient movement on CBCT image clarity without requiring hardware changes.

Innovent to Unveil Phase 3 Gastric Cancer ADC Data at ESMO 2026

Suzhou, China – September 24, 2026 -- Innovent Biologics (HKEX: 01801) will present late-breaking Phase 3 data for its CLDN18.2-targeting antibody-drug conjugate IBI343/TAK-921 at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, running October 23-27.

Phase 3 gastric cancer trial secures late-breaking oral slot

Results from the registrational G-HOPE-001 study, comparing Arcotatug Tavetecan against treatment of physician's choice in previously treated advanced gastric or gastroesophageal junction adenocarcinoma, will be delivered as a late-breaking abstract (LBA77) during the October 23 proffered paper session. Dr. Kohei Shitara of Chiba, Japan, will present the first interim analysis of the randomized, open-label trial.

Sharps Assure Named Top Mail-Back Waste Provider for Dental Offices

New York – – September 24, 2026 -- Better Business Advice has named Sharps Assure a top mail-back medical waste provider for dental offices, citing its sharps container range, dental amalgam disposal product, and prepaid return services.

Sharps Assure offers five container sizes to match variable dental waste volumes

The company provides 1-quart, 1.5-quart, 1-gallon, 2-gallon, and larger-capacity sharps systems, allowing practices to size disposal capacity to procedure volume rather than committing to fixed collection schedules typical of larger healthcare facilities.

Dent Assure Waste Amalgam gives dental offices a dedicated stream for restorative waste

Amalgam waste generated during fillings, removals, or equipment maintenance requires separate handling from standard sharps. Sharps Assure's dedicated product lets practices route this material away from ordinary sharps or office waste streams.

Caliway's CBL-514 Meets Primary Endpoint in Dercum's Disease Trial

Image
Caliway's CBL-514 Meets Primary Endpoint in Dercum's Disease Trial

New Taipei City – September 24, 2026 -- Caliway Biopharmaceuticals (TWSE: 6919) said on September 21 that its Phase 2 CBL-0202DD trial of CBL-514 met its primary efficacy endpoint, delivering statistically significant pain reduction in patients with Dercum's Disease compared with placebo, in both the Full Analysis Set (FAS) and Per-Protocol (PP) populations.

CBL-514 Cuts Pain Scores by 3.1 Points at Week 20 Versus Placebo

In the FAS population, patients treated with CBL-514 achieved a mean pain-score reduction of 3.1 points at Week 20, versus 1.9 points for placebo (p=0.005). In the PP population, the same 3.1-point reduction was measured against a 1.4-point placebo response (p=0.0002).

eHealth, BerniePortal Partner to Expand CHOICE Health Plan Access

Image
eHealth, BerniePortal Partner to Expand CHOICE Health Plan Access

Indianapolis – September 23, 2026 -- eHealth, Inc. (Nasdaq: EHTH) has partnered with benefits administration platform BerniePortal to connect more than 5,000 employers and over 1,000 insurance brokers to individual health coverage options under the newly renamed Custom Health Option and Individual Care Expense Arrangements, or CHOICE.

CMS renamed ICHRA to CHOICE arrangements as of September 3, 2026

The Centers for Medicare and Medicaid Services officially rebranded Individual Coverage Health Reimbursement Arrangements as CHOICE arrangements earlier this month, a shift now embedded in the eHealth-BerniePortal distribution model. Under CHOICE, employers provide employees a defined contribution toward individual health coverage rather than a traditional group plan, shifting cost predictability and plan selection to the employee level.

Eskenazi Joins Faculty of 14th Annual IAFA Aesthetic Symposium

Image
Eskenazi Joins Faculty of 14th Annual IAFA Aesthetic Symposium

Miami Beach, Fla. – September 23, 2026 -- Benjamin Eskenazi MD, FACS, founder of Avabello Aesthetics, has been named to the faculty of the 14th Annual IAFA Aesthetic Symposium, set for the Fontainebleau Miami Beach on November 6-7, 2026.

Dr. Eskenazi will co-instruct a pre-symposium injection masterclass on November 5

The five-hour Anatomy & Injection Masterclass runs from 2:00 to 7:00 p.m. and is led by Professor Sebastian Cotofana, MD, PhD, PhD. The course combines cadaver dissections with live patient injection demonstrations and real-time facial ultrasound, covering neurotoxin treatment of the forehead, glabella and crow's feet, and filler treatment of the temples, tear troughs, cheeks, nasolabial folds, lips, chin and jawline. Dr. Eskenazi will perform live injections alongside co-instructors Terry Alford, DMD; Lanna Cheuck, DO; Barbara Brandt, APRN; Jill Campbell, MSN, FNP-C, CANS; and Shanna Concepcion, RN, CANS.